This article was downloaded by:

On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis and Biophysical and Biological Evaluation of 2'-Modified Antisense Oligonucleotides

C. J. Guinosso^a; G. D. Hoke^a; S. Frier^a; J. F. Martin^a; D. J. Ecker^a; C. K. Mirabelli^a; S. T. Crooke^a; P. D. Cook^a

^a ISIS PHARMACEUTICALS, CARLSBAD, CA, USA

To cite this Article Guinosso, C. J. , Hoke, G. D. , Frier, S. , Martin, J. F. , Ecker, D. J. , Mirabelli, C. K. , Crooke, S. T. and Cook, P. D.(1991) 'Synthesis and Biophysical and Biological Evaluation of 2'-Modified Antisense Oligonucleotides', Nucleosides, Nucleotides and Nucleic Acids, 10: 1, 259 - 262

To link to this Article: DOI: 10.1080/07328319108046455 URL: http://dx.doi.org/10.1080/07328319108046455

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND BIOPHYSICAL AND BIOLOGICAL EVALUATION OF 2'-MODIFIED ANTISENSE OLIGONUCLEOTIDES

C.J. GUINOSSO, G.D. HOKE, S. FRIER, J.F. MARTIN D.J. ECKER, C.K. MIRABELLI, S.T. CROOKE, AND P.D. COOK*

ISIS PHARMACEUTICALS, 2280 FARADAY AVENUE, CARLSBAD, CA 92008, USA

ABSTRACT: A series of 2'-deoxy-2'-substituted adenosine modified oligonucleotides were synthesized and evaluated for their thermodynamic stability (Tms) and resistance to nuclease degradation in fetal calf serum.

To date most efforts directed at enhancing the biological properties of antisense oligonuclotides have been focused on modifying the phosphorus atom of the DNA backbone. 1 In the studies reported herein, we have begun to investigate alternative sites for The oligonucleotides. modified chemically modifying oligonucleotides must be resistant to nucleases yet retain appropriate hybridization properties. Furthermore, we were particularly interested in placing functional groups on the nucleosides so that when the 2'-modified oligonucleotides hybridize with targeted RNA, the functionalities would reside in the minor groove formed by the heteroduplex and proximal to the 2'-hydroxyl group of the targeted RNA. This stems from our desire targeted RNA by a functional group attached catalytic cleavage of to the oligonucleotide complement of the RNA. Other types of pendant groups, of a reactive and non-reactive nature, placed in the minor groove in this manner are also of interest.

Molecular modeling of 2'-O-modified adenine oligonucleotides was utilized to examine the space available in the minor groove of

260 GUINOSSO ET AL.

TABLE 1 - THERMODYNAMIC STABILITY AND NUCLEASE RESISTANCE OF 2'-O-MODIFICATIONS

ISIS # 2'-O-MODIFICATON Tm (\(\Delta\text{Tm.}\text{0}\text{C}\) T1/2 (hr)

ACC GAG GAT CAT GTC GTA CGC (21 mer, pos 1,5,8,11,18)

1772	natural	67
	P=S (1-20)	~57 (-10)
1325	nonyl	51 (-16)
1946	aminopropyl	61 (-6)

CGA CTA TGC AAG TA'C (15 mer, position 14)

1343	natural	53	1.2
1359	P=S (1-20)	46 (-7)	23
1322	nonyl	54 (+1)	5.8
1609	TBOM	52 (-1)	7.0
1947	aminopropyl	53 (0)	7.7

CGA CTA TGC AAA' A'A'C (15 mer, positions 12,13,14)

1732	natural	52	1.0
	P=S (1-14)	~45 (-7)	20
1437	nonyl	49 (-3)	>64
1945	aminopropyl	54 (+2)	17.7

an "A" family of a mixed DNA-RNA duplex for functional groups of interest. The energy minimized structures of the lipophilic n-nonyl and t-butyldimethylsilyl (TBDM) groups reside in the minor groove whereas the aminoethyl-, propyl-, and butyl- groups curl back and appear to form an internal salt with the 3'-phosphate of the modified oligonucleotide. The imidazolylpropyl group in the 2'-position appears to span across the minor groove and towards the opposite 2'-hydroxyl of the RNA complement strand.

$$R = -(CH_2)_8CH_3 \quad NONYL$$

$$R = -(CH_2)_{2-4}NH_2 \quad AMINOALKYLS$$

$$R = -Si(Me)_2C(Me)_3 \quad TBDM$$

$$R = -(CH_2)_3-N \quad IMIDAZOLYL$$

$$PROPYL$$

CHART 1

TABLE 2 - SPECIFICITY OF 2'-O-MODIFICATIONS

X - STRAND 5'-CTC GTA CCA' TTC CGG TCC

Y - STRAND 3'-GAG CAU GGY' AAG GCC AGG (18 mer, 9-position)

Y = T (WATSON-CRICK COMPLEMENT)

Y = A, C, OR G (MISMATCH)

Y = NONE (BULGE LOOP)

Y-O-MODIFICATON	Im (ΔIm, °C)	
natural	63 (0T, -9A,-6G, -14C, -12	2B)
nonyl	58 (0T, -3A, -3G, -6C, -	3B)
TBDM	58 (0T, -4A, -4G, -2C, -	4B)
aminopropyl	60 (0T, -6A, -6G, -12C, -	7B)
	natural nonyl TBDM	nonyl 58 (0T, -3A, -3G, -6C, - TBDM 58 (0T, -4A, -4G, -2C, -

The novel 2'-substituted nucleosides were synthesized by direct coupling of the 2'-OH of protected adenosine with alkylhalides in the presence of sodium hydride in DMF. The 2'-substituted nucleosides, protected by standard procedures, were converted into their 3'-O-β-cyanoethyldiisopropylphosphoramidites which were inserted into specific positions in oligonucleotides via solid phase DNA synthesis. 2'-O-Modified adenosines, synthesized and inserted into sequence specific oligonucleotides, are depicted in CHART 1. A standard RNA synthesis cycle was utilized. The couplings of the modified nucleotides were greater than 94% as determined by

262 GUINOSSO ET AL.

DMT cation evaluations. The oligonucleotides were purified by trityl-on HPLC. The structures of the modified oligonucleotides were confirmed by HPLC and NMR analysis of enzymatic degradations.

Thermodynamic stability of these novel structure classes, as determined by melting studies (Tms, TABLE 1), revealed that up to pendant groups specifically placed within oligonucleotide sequences of 15 to 21 bases in length generally resulted in only a modest effect on Tms compared with the unmodified parent oligonucleotides. The effects on Tms were dependent on location in the sequence in that modifications placed near the 3'-end had less destablizing effects than 5'-end placements. Moreover. oligonucleotides containing 2'-modified adenosines placed near the 3'-end of the oligonucleotide sequences provided resistance to nuclease degradation in 10 % fetal calf serum of 6 to 64-fold greater than the unmodified sequences.

The specificity of the modified adenosines to Watson-Crick base pair with thymidine was determined by preparing a Y strand, an 18 mer with a T (Watson-Crick complement), A, G, C (mismatch), or the deletion of the nucleotide at the 9 position (budge loop). The X complement strand contains the 2'-modified adenosine at the 9th position the 2'-modified adenosine. Data in Table 2 indicate that the specificity of the modified adenosines were retained, ie. their Tm's were greatest when paired with T rather than the mismatch situations of A, G, and C.

The aminopropyladenosine modified oligonucleotides possess hybridization properties similar to unmodified parent oligonucleotides but were significantly enhanced relative to the phosphorothioates. Furthermore, aminopropyladenosine modified oligonuclotides are as resistant to nuclease degradation as the phosphorothioates. The data from these studies suggest that 2'-O-modified oligonuclotides represent a novel and pharmacological distinct class of antisense agents.

REFERENCES

1. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. Edited Jack S. Cohen, CRC Press, Inc. Boca Raton, Florida, 1989; John Goodchild, <u>Bioconiugate Chemistry</u>, 1, 165-187, 1990.